Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia

A CME Friday Satellite Symposium and Webcast Preceding the 66th ASH Annual Meeting

Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration
and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

Location
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, California

Meeting Room
Seaport A-D (Second Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine
Member, Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Richard M Stone, MD
Lunder Family Chair in Leukemia
Chief of Staff
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Eunice S Wang, MD
Chief, Leukemia/Benign Hematology Service
Professor of Oncology, Dept of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York


Andrew H Wei, MBBS, PhD
Professor, Department of Haematology
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
University of Melbourne
Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia

Moderator
Eytan M Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development
in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York



This activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

Discussion Topics

  • MODULE 1: Management of Acute Myeloid Leukemia (AML) in Older Patients
  • MODULE 2: Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML
  • MODULE 3: Role of FLT3 Inhibitors in the Management of AML
  • MODULE 4: Incorporation of IDH Inhibitors into the Care of Patients with AML
  • MODULE 5: Potential Role of Menin Inhibitors and Other Novel Agents in the Management of AML

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recall and apply emerging research data affecting the clinical management of various forms of acute myeloid leukemia (AML).
  • Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for individuals with primary and secondary AML in order to optimize clinical and quality-of-life outcomes.
  • Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for AML, and appraise the current and potential role of this strategy in patient care.
  • Reflect on available research with approved FLT3 inhibitors, and use this information to guide disease management for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Understand published data with and the current role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and IDH1 or IDH2 mutations, and incorporate these agents into management algorithms.
  • Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the potential role of these novel agents.
  • Recollect the mechanisms of action of, available data with and ongoing clinical trials evaluating novel agents and approaches for AML, and appropriately counsel patients about the potential benefits of trial participation.

CE Credit
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Perl — Advisory Committees: Astellas, Bristol Myers Squibb, Curis Inc, Daiichi Sankyo Inc, Rigel Pharmaceuticals Inc, Schrödinger, Syndax Pharmaceuticals; Consulting Agreements: AbbVie Inc, Daiichi Sankyo Inc, Veristat; Contracted Research: Astellas, Daiichi Sankyo Inc; Data and Safety Monitoring Boards/Committees: Beat AML LLC, Foghorn Therapeutics, Leukemia & Lymphoma Society, Veristat. Dr Stone — Consulting Agreements: AbbVie Inc, Amgen Inc, AvenCell, BerGenBio ASA, Bristol Myers Squibb, Celularity, CTI BioPharma, a Sobi Company, Curis Inc, Daiichi Sankyo Inc, GSK, Hemavant, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals, Redona Therapeutics, Rigel Pharmaceuticals Inc; Data and Safety Monitoring Boards/Committees: Aptevo Therapeutics, Epizyme Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc. Dr Wang — Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreement: Kura Oncology; Contracted Research: Arog Pharmaceuticals Inc, Astellas, Biomea Fusion, Cellectis, ImmunoGen Inc, Kura Oncology, Pfizer Inc, Precigen Inc, Sumitomo Dainippon Pharma Oncology Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Daiichi Sankyo Inc, DAVA Oncology, Pfizer Inc; Nonrelevant Financial Relationship: UptoDate (section editor). Prof Wei — Advisory Committees: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Gilead Sciences Inc, GSK, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC; Consulting Agreements: AbbVie Inc, Aculeus Therapeutics, Novartis, Servier Pharmaceuticals LLC, Shoreline Biosciences; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Data and Safety Monitoring Board/Committee: HOVON; Speakers Bureaus: AbbVie Inc, Astellas, Bristol Myers Squibb, Novartis, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Prof Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei receives such a financial benefit.

MODERATOR — Dr Stein — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Syndax Pharmaceuticals.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, and Daiichi Sankyo Inc.

Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101

Meeting Room
Seaport A-D (Second Level)

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of acute myeloid leukemia.

There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Diego, you must also be registered to attend the ASH 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.